Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

PDA-002

Cell therapy (Stem-cell derived) · Cell replacement · developed by Celularity

Phase 2 Most advanced trial (none active)

CELU Developer

1 Registered trials

What is PDA-002?

PDA-002 is a cell therapy consisting of human placenta-derived cells administered intramuscularly. It is being studied for peripheral arterial disease and diabetic foot complications.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (Stem-cell derived)
Mechanism: Cell replacement
Therapy area: Cardiovascular, Endocrine
Developer: Celularity Incorporated (CELU)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02264288	Phase 2	Peripheral Arterial Disease	Terminated	CELU

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetic FootPeripheral Arterial Disease

More from Celularity

CYNK-101 Phase 1/2 PDA001 Phase 2 Taniraleucel Phase 1/2

Sources

ClinicalTrials.gov NCT02264288

Updated Oct 3, 2026. Something wrong or missing? Report it on the CELU page.

Follow CELU, the company behind PDA-002

See CELU's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CELU catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z